Doctors Note Logo

Published on: 8/18/2026

Why Adult Skeletons Weaken Rapidly: HPP Next Steps

Rapid bone weakening in adults can signal hypophosphatasia (HPP), a rare genetic condition in which low alkaline phosphatase activity blocks proper mineralization, leading to stress fractures, recurrent metatarsal breaks, pseudofractures, early tooth loss, muscle pain, and fatigue that is often misdiagnosed as osteoporosis or fibromyalgia. Key clues include a persistently low serum alkaline phosphatase level, elevated vitamin B6 and inorganic pyrophosphate, and a family history of fragile bones or dental problems, and confirmation usually involves ALPL gene testing. Next steps typically include specialist referral to endocrinology or metabolic bone disease, avoiding bisphosphonates and high-dose antiresorptive drugs that may worsen HPP, plus enzyme replacement therapy for eligible patients and physical therapy for mobility. Several factors influence how quickly bone loss progresses and which treatments are appropriate, so see below to understand more.

Because low bone density, fractures, and joint pain have many possible causes, mapping your specific pattern of symptoms is the fastest way to know whether HPP, osteoporosis, vitamin D deficiency, or something else deserves attention first. Take a free, instant, online symptom check to organize what you are experiencing, learn which conditions match your profile, and walk into your next appointment with clear questions and the right tests to request.

Last reviewed for medical accuracy: 08/18/2026

answer background

Explanation

Why Adult Skeletons Weaken Rapidly: Understanding Hypophosphatasia (HPP) and Low Alkaline Phosphatase in Adults

Hypophosphatasia (HPP) is a rare metabolic bone disease caused by mutations in the ALPL gene, leading to chronically low alkaline phosphatase in adults. Alkaline phosphatase (ALP) is an enzyme crucial for bone mineralization—without enough of it, bones can lose strength, become painful, and fracture easily. Although HPP is often diagnosed in childhood, a milder form may go unrecognized until adulthood, when rapid bone weakening or stress fractures prompt investigation.

Below, we’ll explain why an adult skeleton can weaken rapidly in HPP, outline the next steps for diagnosis and management, and offer practical advice—without sugar-coating or causing unnecessary worry.


1. Why Bones Weaken in Adult HPP

In healthy adults, ALP breaks down inorganic pyrophosphate, a natural inhibitor of bone mineralization. When ALP levels are low:

  • Inorganic pyrophosphate accumulates around bone-forming cells.
  • Hydroxyapatite crystals (the mineral “glue” of bone) cannot form or grow properly.
  • Bones lose density and structural integrity over time.
  • Microfractures can develop under normal stress, leading to pain and more serious breaks.

Key factors in rapid bone weakening:

  • Chronic low alkaline phosphatase in adults: The hallmark of HPP. Persistent low ALP impairs ongoing bone remodeling and repair.
  • Accumulation of toxic substrates: Substances like pyridoxal 5’-phosphate (active vitamin B6) build up, contributing to bone pain and muscle weakness.
  • Stress fractures: Often the first sign in adults—small cracks in weight-bearing bones that worsen without proper treatment.

2. Recognizing Adult HPP

Adult HPP can mimic osteoporosis or other bone-weakening conditions, so awareness of key clues is vital:

Common Symptoms

  • Chronic bone and joint pain, often in feet, hips, or lower legs
  • Recurrent stress fractures or delayed union of fractures
  • Muscle weakness, fatigue, or limited mobility
  • Dental issues, such as early loss of permanent teeth

Laboratory Clues

  • Persistently low serum ALP activity (even “borderline” low values matter)
  • Elevated substrates normally broken down by ALP (for example, vitamin B6 derivatives)
  • Normal or high blood calcium and phosphate levels (distinguishes HPP from other causes of low ALP)

Family History

  • A relative with unexplained early fractures, dental problems, or known HPP increases suspicion.

3. Diagnostic Steps

If you suspect HPP due to low alkaline phosphatase in adults, a systematic approach helps confirm the diagnosis:

  1. Repeat ALP Testing

    • Confirm persistent low levels (lab-to-lab variations can occur).
    • Consider age- and sex-adjusted reference ranges.
  2. Additional Blood Tests

    • Measure vitamin B6 (pyridoxal 5’-phosphate).
    • Check calcium, phosphate, and parathyroid hormone (PTH) levels.
  3. Genetic Testing

    • ALPL gene sequencing to identify causative mutations.
    • Genetic counseling helps interpret results and family risk.
  4. Imaging

    • X-rays or MRI to detect stress fractures or bone demineralization.
    • Dual-energy X-ray absorptiometry (DXA) for bone density (may show mild to moderate reductions).
  5. Specialist Referral

    • Endocrinologist or metabolic bone disease specialist for comprehensive evaluation.
    • Dental assessment if early tooth loss or alveolar bone issues are present.

4. Next Steps: Management and Treatment

While adult HPP cannot be cured, targeted therapies and supportive measures can stabilize bone health, relieve symptoms, and improve quality of life.

A. Enzyme Replacement Therapy

  • Asfotase alfa
    • A recombinant form of ALP approved for pediatric-onset HPP; sometimes used off-label in adults.
    • Helps clear toxic substrates, promote bone mineralization, and reduce pain.
    • Requires regular subcutaneous injections and monitoring.

B. Bone-Building Medications

  • Teriparatide (PTH analog)
    • Can stimulate bone formation in selected adults with severe HPP.
    • Off-label use; benefits and risks should be weighed by a bone specialist.

C. Pain Control and Physical Therapy

  • Non-opioid pain relievers (acetaminophen or NSAIDs, if tolerated)
  • Tailored exercise programs to build muscle and improve balance
  • Assistive devices (braces, orthotics) to reduce fracture risk and support joints

D. Nutritional Support

  • Adequate calcium and vitamin D to support overall bone health
  • Balanced diet rich in protein, fruits, and vegetables
  • Avoid excessive calcium supplements if blood levels are high

E. Lifestyle and Fall Prevention

  • Home safety evaluation to minimize tripping hazards
  • Strength and balance training (yoga, Tai Chi)
  • Quit smoking and limit alcohol, both of which can worsen bone health

F. Multidisciplinary Care

  • Coordination between endocrinologists, orthopedic surgeons, dentists, physiotherapists, and genetic counselors
  • Regular follow-up visits to monitor bone density, laboratory values, and treatment response

G. Clinical Trials and Emerging Therapies

  • Participation in research studies may provide access to new treatments
  • Contact specialized bone disease centers or patient advocacy groups for trial information

5. Monitoring and Long-Term Outlook

  • Regular lab tests (ALP, vitamin B6) to gauge enzyme activity
  • Periodic imaging (DXA scans, X-rays) to track bone density and detect new fractures
  • Adjust therapy based on symptom changes, side effects, or new research findings
  • With proper management, many adults with HPP can maintain mobility, reduce pain, and lower their fracture risk

6. Self-Assessment and When to Seek Help

If you have persistent bone pain, unexplained stress fractures, or suspect your ALP levels are low, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. It can help clarify your symptoms and guide you toward the right specialist.

Always speak to a doctor if you experience:

  • Sudden, severe bone pain or swelling
  • Signs of infection (fever, redness around a fracture)
  • Difficulty walking or bearing weight
  • Any symptom that feels out of the ordinary or life threatening

Key Takeaways

  • Hypophosphatasia in adults stems from chronically low alkaline phosphatase, leading to poor bone mineralization and rapid weakening.
  • Early recognition—through lab tests, imaging, and genetic analysis—allows timely intervention.
  • Management includes enzyme replacement, targeted bone-building drugs, pain control, physical therapy, and lifestyle changes.
  • Regular monitoring and a coordinated care team optimize outcomes.
  • Use tools like the Ubie Symptom Checker to better understand your symptoms, and always consult your doctor about serious concerns.

(References)

  • * Morbach H, Hedrich CM, Beer M, Girschick HJ. Autoinflammatory bone disorders. Clin Immunol. 2013 Jun;147(3):185-96. doi: 10.1016/j.clim.2012.12.012. Epub 2013 Jan 5. PMID: 23369460.

  • * Feingold KR, Adler RA, Ahmed SF, Anawalt B, Blackman MR, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hamilton E, Hofland J, Jan de Beur S, Kalra S, Kaltsas G, Kapoor N, Kim M, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Sperling MA, Stratakis CA, Trence DL, Wilson DP, Lewiecki EM. Osteoporosis: Clinical Evaluation. 2000. PMID: 25905277.

  • * Feingold KR, Adler RA, Ahmed SF, Anawalt B, Blackman MR, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hamilton E, Hofland J, Jan de Beur S, Kalra S, Kaltsas G, Kapoor N, Kim M, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Sperling MA, Stratakis CA, Trence DL, Wilson DP, Marini JC, Dang Do AN. Osteogenesis Imperfecta. 2000. PMID: 25905334.

  • * Uebelhart B, Rizzoli R. [Bone diseases]. Rev Med Suisse. 2016 Jan 13;12(500):49-54. PMID: 26946704.

  • * Briot K, Roux C. Adult hypophosphatasia. Arch Pediatr. 2017 May;24(5S2):5S71-5S73. doi: 10.1016/S0929-693X(18)30018-6. PMID: 29405936.

  • * Kishnani PS, Rockman-Greenberg C, Rauch F, Bhatti MT, Moseley S, Denker AE, Watsky E, Whyte MP. Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia. Bone. 2019 Apr;121:149-162. doi: 10.1016/j.bone.2018.12.011. Epub 2018 Dec 18. PMID: 30576866.

  • * Schini M, Vilaca T, Gossiel F, Salam S, Eastell R. Bone Turnover Markers: Basic Biology to Clinical Applications. Endocr Rev. 2023 May 8;44(3):417-473. doi: 10.1210/endrev/bnac031. PMID: 36510335; PMCID: PMC10166271.

  • * Bertoldo F, Tripepi G, Zaninotto M, Plebani M, Scillitani A, Varenna M, Crotti C, Cipriani C, Pepe J, Minisola S, Pugliese F, Guarnieri V, Baffa V, Torres MO, Zanchetta F, Fusaro M, Rossini M, Brandi ML, Egan CG, Simioni P, Arcidiacono GP, Sella S, Giannini S. Possible role of bone turnover markers in the diagnosis of adult hypophosphatasia. J Bone Miner Res. 2024 Dec 31;40(1):79-86. doi: 10.1093/jbmr/zjae177. PMID: 39498489; PMCID: PMC11983269.

  • * Gill AS, Sharma P, Nassar M, Marte E. Hypophosphatasia: A case report. World J Clin Cases. 2025 Jul 26;13(21):103642. doi: 10.12998/wjcc.v13.i21.103642. PMID: 40726933; PMCID: PMC12068182.

  • * Susin C, Stadler AF, Haas A, Albandar JM. Periodontal Manifestations of Systemic Diseases. J Periodontal Res. 2025 Sep 16. doi: 10.1111/jre.70034. Epub 2025 Sep 16. PMID: 40956006.

Thinking about asking ChatGPT?Ask me instead

Tell your friends about us.

We would love to help them too.

smily Shiba-inu looking

For First Time Users

What is Ubie’s Doctor’s Note?

We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.

Was this page helpful?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.